China approves Novartis' multiple sclerosis treatment Mayzent - (The Telegram via NewsPoints Desk)

  • Novartis said that China's National Medical Products Administration has approved Mayzent to treat relapsing multiple sclerosis in adults, as reported The Telegram.

  • Other drugs approved in China to treat multiple sclerosis include Novartis' Gilenya, Bayer's Betaferon and Sanofi's Aubagio.

To read more NewsPoints articles, click here.